Evaluation of Same-Day versus Next-Day Implantation of Intracanalicular Dexamethasone for the Control of Postoperative Inflammation and Pain Following Cataract Surgery

Bobby Saenz 1
Tanner J Ferguson 2
Noelle Abraham 1
Brett H Mueller 1
Gregory D Parkhurst 1

1Parkhurst NuVision, San Antonio, TX, USA; 2Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA

Purpose: To evaluate the safety and efficacy of a sustained-release intracanalicular dexamethasone insert for postoperative inflammation and pain implanted in a clinical setting preoperatively or on postoperative day 1.

Methods: Single-site, retrospective, contralateral eye study of patients undergoing cataract surgery. Included were subjects with a dexamethasone intracanalicular insert implanted in the clinic immediately prior to surgery in one eye (same-day) and on postoperative day 1 (POD1) in the contralateral eye. The primary outcome measure was the resolution of anterior chamber inflammation at 1 week postoperative. Secondary outcome measures included proportion of eyes requiring additional therapy for pain and inflammation through 1 month as well as the number of eyes with IOP spikes above baseline. Safety measures included adverse events through 1 month postoperative.

Results: Sixty-two eyes of 31 subjects were included in the case series. At 1 week postoperative, 52% of the eyes (n = 16) achieved complete resolution of inflammation in the same-day group and 58% (n = 18) met this endpoint at 1 week in the POD1 group. One subject in the same-day group required additional therapy for rebound inflammation and no eyes required additional therapy in the POD1 group. There were no reports of pain at 1 week or 1 month in either group. There were no implant-related adverse events in either group.

Conclusion: The favorable results of this study indicate that the sustained-release dexamethasone insert can be safely implanted in the clinic either preoperatively on the day of surgery or on postoperative day 1 for the control of pain and inflammation following cataract surgery.

Keywords: cataract surgery, dexamethasone, intracanalicular, ocular inflammation, ocular pain

Introduction
Topical corticosteroids are a mainstay of medication regimens following cataract surgery to mitigate postoperative inflammation and patient discomfort. Despite the continued innovation within the realm of cataract surgery translating to excellent outcomes and safety in cataract surgery, postoperative inflammation remains a common occurrence and must be appropriately recognized and treated to prevent further sequelae. If uncontrolled or not adequately treated, persistent ocular inflammation can be subjectively perceived by the patient as pain and photophobia and can clinically manifest with elevated intraocular pressure (IOP), synechiae...
formation and macular edema. Optimal control of postoperative inflammation is paramount for patient satisfaction and achieving the best surgical outcome.

Topical corticosteroids, when administered correctly, are an excellent option for management of postoperative inflammation and remain widely used by cataract surgeons and clinicians. However, adherence to drops, complex medication regimens and difficulties with instillation are well-recognized barriers to effective treatment with topical therapies across the field of ophthalmology. This is particularly true in the cataract surgery population, a cohort of patients that not uncommonly has minimal to no experience with regular eyedrop use. A prior study evaluating patients’ eyedrop instillation techniques noted greater than 90% of the patients incorrectly performed the technique. Furthermore, in monitoring subjects, this aforementioned study also reported a notable discrepancy between the patients’ perception of their ability to correctly instill the drop and the observed technique.

In recent years, considerable innovation has occurred across ophthalmology as it relates to drug delivery to overcome the aforementioned obstacles with topical medication. Recently, a sustained-release dexamethasone intracanalicular depot (Dextenza, Ocular Therapeutix, Bedford, MA) was approved by the FDA for postoperative ocular inflammation and pain. The insert, which is placed within the canaliculcus and contains 0.4 mg of active dexamethasone, aims to provide a sustained and tapered release of drug to the ocular surface over the course of 30 days. Clinical trials leading to its approval reported favorable results regarding postoperative inflammation and subjective pain. Further, additional recently published work has highlighted the value of the insert beyond cataract surgery including a recent study in patients following photorefractive keratectomy (PRK) by Ibach et al that showed patients strongly preferred the insert compared to topical steroid drops.

This present study aimed to evaluate the outcomes of cataract surgery patients implanted in an office setting with a dexamethasone intracanalicular insert preoperatively on the day of surgery or on postoperative day 1. To our knowledge, no prior studies have assessed outcomes with the dexamethasone intracanalicular insert placed preoperatively in the clinic either same day or on postoperative day 1. To collect data, a retrospective, consecutive case review was performed.

**Methods**

This was a single-site, retrospective review performed at a single site (San Antonio, TX). A de-identified data set was generated for analysis. This study was conducted in compliance with the Declaration of Helsinki and was reviewed and approved by the Advarra Institutional Board with a waiver of consent due to the retrospective nature of the study.

**Inclusion/Exclusion**

Data in the consecutive case series were collected for subjects 18 years or older with visually significant cataracts undergoing standard phacoemulsification without adjunctive use of a femtosecond laser from May to September 2020. All data was collected and evaluated from a single site, in which the optometrist implanted all inserts in the clinic setting. Included were subjects with a dexamethasone intracanalicular insert implanted immediately prior to surgery in one eye and on postoperative day 1 in the contralateral eye, constituting a contralateral eye study. Subjects with the insert placed in both eyes on postoperative day 1 were excluded. Subjects with the insert placed in both eyes on the day of surgery were excluded. The eyes implanted on the day of surgery will be denoted the same-day surgery group for this report; the eyes implanted with the insert on postoperative day 1 were postoperative day 1 group, or POD1. Postoperatively, both groups were uniformly started on a topical medication regimen that included besifloxacin 0.6% (Besivance, Bausch & Lomb, Bridgewater, NJ) four times daily for 9 days starting 2 days before surgery and bromfenac 0.07% (Prolensa, Bausch & Lomb, Bridgewater, NJ) once daily for 4 weeks starting the day of surgery. Exclusion criteria included eyes with a history of corneal pathology (eg, Fuchs’), history of uveitis, or a history of severe glaucoma.

**Main Outcome Measures**

Preoperative data, collected in the baseline visit that typically occurred 1–2 weeks prior to the surgery, was used to establish a baseline. Postoperatively, data was collected at 1 day, 1 week and 1 month. At each time point, anterior chamber inflammation, quantitatively assessed by cells and flare, was graded 0–4 + based on the Standardization of Uveitis Nomenclature (SUN) grading scheme on slit-lamp biomicroscopy. Intraocular pressure (IOP) via Goldmann Applanation Tonometry (GAT) was also assessed. Subjects were surveyed on their pain with dichotomous form of questioning (with or without pain).

The primary outcome measure was the resolution of anterior chamber (AC) inflammation at the 1-week visit. Secondary outcome measures included the proportion of eyes requiring additional therapy for pain and inflammation through 1 month postoperative. Other secondary measures included the number of patients with elevated IOP >10 mmHg above
baseline as well as the incidence of adverse events through 1 month postoperative.

**Study Device**
The sustained-release depot is a single-use insert containing 0.4 mg of active dexamethasone designed for intracanalicular use. The device was approved by the FDA for the treatment of ocular inflammation and pain associated with ocular surgery. The insert’s composition is polyethylene glycol (PEG) that utilizes hydrogel technology to deliver dexamethasone. The insert is also conjugated with fluorescein that enables visualization of the insert after it is inserted into the vertical canaliculus. With contact of fluid, the insert swells to securely conform to the canalicular location, allowing direct delivery of the preservative-free dexamethasone on to the ocular surface over the course of 30 days. Over time, with continuous hydrolysis, the insert gradually softens and degrades and is eventually cleared through the nasolacrimal drainage system without the need for removal. **Figure 1** depicts the technique for implantation of the insert.

**Statistical Analysis**
Unpaired, parametric *t*-tests were performed at the 3 times points (1 day, 1 week and 1 month) postoperatively to compare the degree of inflammation between the two groups. The level of significance was taken to be 0.05. No formal power calculations were performed to assess sample size. All statistical analyses were performed using Prism 9 software (GraphPad Software, Inc.).

**Results**

**Patient Demographics**
Sixty-two eyes of 31 subjects were successfully implanted in the clinic with the dexamethasone insert either on the day of surgery or POD1. Data of this case series were available at 1 day, 1 week, and 1 month for all
eyes. All subjects were evaluated by the same provider (B. S) at 1 day, 1 week and 1 month. The mean age of the subjects included in this series was 69.5 ± 9.0 years with 17/31 subjects being female. The baseline characteristics of the 31 subjects are summarized in Table 1.

### Efficacy

In the same-day group, all eyes had presence of inflammation at the 1-day postoperative visit ranging from 1 to 2+ AC cell. By 1 week, 52% (n=16) of the eyes achieved complete resolution of inflammation; at 1 month, 100% of the eyes were absent of inflammation. One subject exhibited rebound inflammation 5 weeks after surgery that responded to a 3-week taper of topical loteprednol.

In the same-day group, 1 (3%) subject had evidence of IOP elevation >10 mmHg at the 1-week visit from 14 (baseline) mmHg to 26 mmHg. This subject was started on timolol once daily for 3 weeks and IOP was 16 mmHg at 1 month. In this group, 100% of the subjects reported an absence of pain at the 1-week and 1-month time points.

In the POD1 group, all eyes included in the group had evidence of inflammation ranging from 1 to 2+ AC cells at 1 day postoperative. At 1 week, 58% (n=18) of eyes included in the series had complete resolution of inflammation. At 1 month, 97% (n=30) showed complete resolution of inflammation; there was 1 subject with evidence of 0.5+ AC cells at the 1-month visit. No eyes required additional or adjunct therapy for control of inflammation. There was no significant difference in the degree of inflammation between the POD1 and the same-day group at 1 day (p=0.17), 1 week (p=0.27) or 1 month (p=0.32).

Table 2 compares the presence of anterior chamber inflammation at each time point.

In the POD1 group, at 1 week, there were no instances of IOP elevation >10 mmHg above baseline. No eyes were treated with additional IOP-lowering medication. The mean IOP at 1 week and 1 month was 14.3 ± 4.4 mmHg and 13.1 ± 4.1 mmHg, respectively. In this cohort, at 1 week and 1 month, 100% of the subjects reported complete absence of pain.

There were no canalicular-related complications or adverse events related to implantation of the depot in either group. No patients in either the POD1 or same-day group required removal of the insert.

### Discussion

This retrospective, contralateral eye study demonstrates that the 0.4 mg dexamethasone insert is a safe and effective option for control of postoperative inflammation following cataract surgery. In this series, in both the same-day surgery and POD1 group, greater than half the eyes in each group had complete resolution of AC inflammation by 1 week after surgery. By 1 month, there was only a single eye with evidence of inflammation between the two cohorts. In addition, there were no reports of pain at the 1-week or 1-month time point in either group, supporting the anti-inflammatory properties of the insert.

---

**Table 1** Demographic and Clinical Characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y), mean ± SD</td>
<td>69.5 ± 9.0</td>
</tr>
<tr>
<td>Range (y)</td>
<td>40–87</td>
</tr>
<tr>
<td>Sex, n, M/F</td>
<td>14/17</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td>White 20 (58)</td>
</tr>
<tr>
<td></td>
<td>Hispanic 9 (30)</td>
</tr>
<tr>
<td></td>
<td>African-American 1 (6.3)</td>
</tr>
<tr>
<td></td>
<td>Asian 1 (6.3)</td>
</tr>
<tr>
<td>Baseline IOP (mmHg), mean ± SD</td>
<td></td>
</tr>
<tr>
<td>Same-day group</td>
<td>15.5 ± 4.2</td>
</tr>
<tr>
<td>POD1 group</td>
<td>15.5 ± 4.0</td>
</tr>
</tbody>
</table>

**Abbreviations:** IOP, intraocular pressure; SD, standard deviation.

---

**Table 2** Summary of the Presence of Anterior Chamber Inflammation at Each Time Point

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>1 Day</th>
<th>1 Week</th>
<th>1 Month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Same Day, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. with no</td>
<td>0 (0)</td>
<td>16 (52)</td>
<td>31 (100)</td>
</tr>
<tr>
<td>inflammation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. with 0.5+ cell</td>
<td>0 (0)</td>
<td>10 (32)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>No. with 1+ cell</td>
<td>15 (48)</td>
<td>5 (16)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>No. with 2+ cell</td>
<td>16 (52)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Postoperative Day 1, n (%)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No. with no inflam</td>
<td>0 (0)</td>
<td>18 (5)</td>
<td>30 (97)</td>
</tr>
<tr>
<td>No. with 0.5+ cell</td>
<td>1 (3)</td>
<td>11 (36)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>No. with 1+ cell</td>
<td>7 (23)</td>
<td>2 (6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>No. with 2+ cell</td>
<td>23 (74)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

**Note:** At each time point, anterior chamber inflammation, quantitatively assessed by cells and flare, was graded 0–4+ based on the Standardization of Uveitis Nomenclature (SUN) grading scheme on slit-lamp biomicroscopy.
The results of this study indicate that the dexamethasone depot can be safely inserted preoperatively on the day of surgery or on postoperative day 1 for postoperative control of inflammation. Both groups demonstrated favorable results with regard to resolution of inflammation and there was no significant difference in clinical outcomes between the two eyes. Although the clinical trials and post-approval studies have primarily assessed the efficacy of the insert when inserted on the day of surgery following cataract surgery, the results of this present study offer meaningful implications for clinical practice. The favorable results with insertion either on the day of surgery or on postoperative day 1 promote the versatility of the device and indicate the insert can safely be inserted preoperatively on the day of surgery or on postoperative day 1. Additionally, to our knowledge, this study represents the first study to report outcomes assessing preoperative insertion of the dexamethasone insert.

Several prior studies have highlighted the safety and efficacy of the dexamethasone insert evaluated in this present study with regards to postoperative pain and inflammation. In a recent study by Tyson et al., a prospective, multicenter study compared the insert versus placebo and reported a greater proportion of patients in the dexamethasone insert arm met endpoints assessing the absence of pain and anterior chamber inflammation at key postoperative time points. In addition to excellent efficacy, the safety profile reported across these studies was also favorable with the dexamethasone arm demonstrating a similar safety profile in comparison to placebo. Furthermore, there were no intracanalicular complications, supporting the ease of insertion. Although limited by the lack of a control group, the findings of this present report corroborate those results described in the aforementioned RCTs in a real-world, clinical setting.

Adherence to topical medication regimens is a complex issue impacted by a multitude of factors. Factors such as inexperience, age, finance and complexity of medication regimens are all important considerations when starting a patient on a topical medication regimen. Postoperative medication regimens following cataract surgery, in particular corticosteroids, can add a layer of complexity for the patient owing to the tapering schedule and difference in dosing schedules between the eyes. Moreover, many patients who undergo cataract surgery are on existing medications and having to wait >5 minutes prior to drop instillation for each medication which creates a sizable burden. These challenges have prompted the development of nontopical medication options such as the sustained-release intracanaliculardescribe insert evaluated in this present study.

There are considerations unique to corticosteroids as it relates to nontopical and/or sustained drug-delivery medication options. The sustained-release insert described herein offers attributes that overcome the potential side effects and challenges of topical corticosteroid use. Topical agents, which are instilled intermittently, inevitably lead to variability in drug concentration owing to the poor bioavailability of the agent. The insert’s intracanalicular location, with proximity to the ocular surface, permits to offer a superior bioavailability profile with improved consistency of drug concentration in contrast to topical administration. The tapered delivery of drug from the insert over the course of 30 days minimizes the risk for rebound inflammation, which can occur with abrupt discontinuation of topical steroids. In addition, the preservative-free composition of the insert circumvents issues with preservatives and ocular surface toxicity, a well-recognized problem with long-term use of topical drops.

This study is not without limitations. The sample size was modest in size and was performed at a single site. There was no control arm of patients using topical medications for comparison. The subjective method of pain assessment employed in this study is not standardized and is an acknowledged drawback of this study. Despite these limitations, the results of this contralateral eye study are compelling as the results are sourced from a real-world clinical population without strict inclusion criteria. The real-world study design provides results that are possibly generalizable to other practicing clinicians and supports the use of the insert in an office setting for control of postoperative inflammation.

Conclusion

The challenges of topical medication use are widespread and well recognized across ophthalmology. The results of the present study favor the use of the dexamethasone insert as a means to optimize medication delivery for patients without compromising safety or efficacy. The favorable outcomes in this report demonstrate that the sustained-release dexamethasone insert placed in the clinic either preoperatively on the day of surgery or postoperative day 1 is a safe and effective option for control of postoperative inflammation and pain following cataract surgery.
Disclosure
Dr Bobby Saenz reports grants from Ocular Therapeutix, during the conduct of the study; personal fees from Ocular Therapeutix, outside the submitted work. Dr Tanner J Ferguson reports personal fees from Equinox and Glaukos, outside the submitted work. The authors report no other conflicts of interest in this work.

References